1. Quick Facts
Category: Mitochondrial-Targeted Tetrapeptide
Risk Level: Experimental
Research Status: Moderate Human Research
Administration: Subcutaneous Injection
Typical Frequency: Daily
Estimated Half-Life: Approximately 2–5 Hours
Primary Research Interest: Mitochondrial Function / Cardiac Support / Healthy Aging Research
This material is provided strictly for educational and informational purposes related to peptide research and experimental mitochondrial compounds. SS-31 (Elamipretide) is a biologically active mitochondrial-targeted peptide currently under investigation for a variety of mitochondrial and age-related conditions. Information presented here should not be interpreted as medical advice, treatment recommendations, or encouragement of unsupervised use.
2. Summary
SS-31, also known as Elamipretide, is an experimental mitochondrial-targeted tetrapeptide designed to interact with cardiolipin, a phospholipid located within the inner mitochondrial membrane. Unlike many peptides that influence hormonal pathways, SS-31 is designed to act directly at the mitochondrial level.
Research interest in SS-31 primarily centers around mitochondrial dysfunction, cardiac support, exercise capacity, fatigue reduction, recovery enhancement, and healthy-aging-associated applications.
What People Commonly Claim
- Improved mitochondrial function
- Increased cellular energy production
- Better exercise tolerance
- Cardiac support benefits
- Reduced fatigue
- Longevity-associated benefits
What the Literature Actually Shows
- SS-31 (Elamipretide) is a mitochondria-targeted tetrapeptide designed to interact with cardiolipin within the inner mitochondrial membrane.
- Research suggests potential improvements in mitochondrial efficiency and cellular bioenergetics.
- Human studies have investigated mitochondrial disorders, cardiac disease, and age-related functional decline.
- Early clinical findings were encouraging in several areas of research.
- Later Phase 3 studies failed to meet some primary efficacy endpoints despite promising earlier findings.
- The compound remains investigational and has not achieved widespread clinical adoption.
3. Reconstitution Guide
- Vial Size: 50 mg
- Dilutant Type: BAC Water
- Amount of Dilutant Added: 2.5 mL
- Final Concentration: 20.00 mg/mL
At this concentration:
• 2.5 mg = 0.125 mL (12.5 units)
• 5.0 mg = 0.250 mL (25.0 units)
• 7.5 mg = 0.375 mL (37.5 units)
• 10 mg = 0.500 mL (50.0 units)
*Different vial sizes may limit reconstitution volume. If your product differs from the specifications listed here, please use the Peptide Calculator to calculate custom concentrations and dosing protocols.
4. Route of Administration
SS-31 is most commonly administered as a subcutaneous injectable mitochondrial-targeted peptide.
- Primary Route: SubQ Injection
- Preferred Timing: Flexible daily administration timing
- Administration Notes: Long-term consistency is commonly emphasized because any measurable effects are generally described as gradual and cumulative.
5. Common Research Protocols
- Product Strength: 20.00 mg/mL
- Typical Delivered Amount: 2.5 mg/day × 2 weeks, then 5.0 mg/day × 2 weeks, then 7.5 mg/day × 2 weeks, then 10 mg/day × 4 weeks
- Frequency: Daily
- Cycle Length: 10 weeks on / 2 weeks off
- Special Notes: SS-31 has been investigated in cardiovascular, mitochondrial, and age-related disease research. Human clinical studies remain ongoing, and optimal dosing strategies have not been fully established. Many researchers emphasize consistency because mitochondrial adaptations are generally believed to occur gradually over time.
6. Mechanism of Action
SS-31 is believed to selectively target mitochondrial membranes and interact with cardiolipin, a phospholipid that plays an important role in mitochondrial structure, electron transport chain function, and cellular energy production.
Unlike many peptides that act through endocrine or hormonal pathways, SS-31 is designed to act directly at the mitochondrial level.
Potential downstream effects discussed in the literature include:
- Improved mitochondrial efficiency
- Reduced oxidative stress signaling
- Enhanced cellular energy production
- Potential cardiac support
- Reduced mitochondrial membrane damage
- Improved exercise recovery signaling
- Support for mitochondrial bioenergetics
The compound is often discussed as one of the most advanced mitochondrial-targeted peptide therapeutics currently under investigation.
7. Potential Benefits
- Potential mitochondrial support
- Improved exercise tolerance
- Reduced fatigue
- Possible cardiac-support effects
- Enhanced recovery signaling
- Potential support for healthy-aging pathways through mitochondrial function
- Improved cellular energy efficiency
8. Potential Risks / Side Effects
Experimental
- Limited long-term human safety data
- Injection-site irritation
- Fatigue or lethargy
- Dizziness
- Unknown long-term mitochondrial effects
- Potential cardiovascular signaling changes
- Clinical efficacy remains uncertain for several investigated conditions
9. Half-Life
SS-31 is commonly discussed as having an estimated plasma half-life of approximately 2–5 hours.
Despite its relatively short circulating duration, downstream mitochondrial effects may accumulate gradually over time due to repeated interaction with mitochondrial membranes and bioenergetic pathways.
10. Storage Information
- Store refrigerated before and after reconstitution
- Protect from direct light exposure
- Avoid repeated freeze-thaw cycles
- Maintain sterile handling practices during preparation
11. Contraindications / Warnings
- Pregnancy or breastfeeding
- Known hypersensitivity to peptide compounds
- Severe metabolic disorders
- Advanced cardiovascular disease without appropriate medical oversight
- Participation in concurrent investigational therapies without proper supervision
12. Further Study
Overview Article
Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential
Mechanism of Action Research
Mitochondrial Protein Interaction Landscape of SS-31
Human Clinical Evidence
Randomized Dose-Escalation Trial of Elamipretide in Adults with Primary Mitochondrial Myopathy
Human Clinical Evidence
A Randomized Crossover Trial of Elamipretide in Adults with Primary Mitochondrial Myopathy
Human Clinical Evidence
Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy (MMPOWER-3)
Aging & Longevity Research
13. Research References
- PubMed
- PubMed Central (PMC)
- NIH Publications
- Mitochondrial physiology literature
- Peer-reviewed cardiology journals
- Mitochondrial disease research
- Cellular bioenergetics and aging research
14. Last Reviewed
June 2026